Last reviewed 2026-04-23 · How we verify

AN9025 oral capsule

Adlai Nortye Biopharma Co., Ltd. · Phase 1 active Small molecule

AN9025 oral capsule is a Small molecule drug developed by Adlai Nortye Biopharma Co., Ltd.. It is currently in Phase 1 development.

At a glance

Generic name	AN9025 oral capsule
Sponsor	Adlai Nortye Biopharma Co., Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AN9025 oral capsule CI brief — competitive landscape report
AN9025 oral capsule updates RSS · CI watch RSS
Adlai Nortye Biopharma Co., Ltd. portfolio CI

Frequently asked questions about AN9025 oral capsule

What is AN9025 oral capsule?

AN9025 oral capsule is a Small molecule drug developed by Adlai Nortye Biopharma Co., Ltd..

Who makes AN9025 oral capsule?

AN9025 oral capsule is developed by Adlai Nortye Biopharma Co., Ltd. (see full Adlai Nortye Biopharma Co., Ltd. pipeline at /company/adlai-nortye-biopharma-co-ltd).

What development phase is AN9025 oral capsule in?

AN9025 oral capsule is in Phase 1.

Manufacturer: Adlai Nortye Biopharma Co., Ltd. — full pipeline
Compare: AN9025 oral capsule vs similar drugs
Pricing: AN9025 oral capsule cost, discount & access